Top Page
Micro-X Ltd.
(Sydney:MX1)
Micro-X Ltd. (MX1) vs. iShares MSCI Australia ETF (EWA)
Micro-X Ltd. Business Overview & Revenue Model
Micro-X Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.76M | 13.05M | 15.22M | 15.01M | 8.97M | 3.77M |
| Gross Profit | 402.00K | 10.32M | 5.74M | -7.11M | -12.33M | -12.96M |
| EBITDA | -13.47M | -11.76M | -14.35M | -15.54M | -19.02M | -13.61M |
| Net Income | -11.83M | -13.89M | -9.77M | -10.75M | -17.09M | -14.73M |
Balance Sheet | ||||||
| Total Assets | 17.41M | 22.11M | 26.89M | 30.30M | 31.28M | 44.68M |
| Cash, Cash Equivalents and Short-Term Investments | 4.90M | 3.24M | 3.23M | 5.22M | 10.30M | 30.14M |
| Total Debt | 5.13M | 6.53M | 3.99M | 4.70M | 5.31M | 5.84M |
| Total Liabilities | 11.82M | 14.56M | 12.63M | 13.17M | 12.05M | 10.53M |
| Stockholders Equity | 5.59M | 7.55M | 14.26M | 17.13M | 19.22M | 34.15M |
Cash Flow | ||||||
| Free Cash Flow | -9.77M | -8.69M | -6.80M | -11.77M | -19.22M | -10.76M |
| Operating Cash Flow | -9.72M | -8.59M | -6.43M | -10.99M | -18.11M | -9.86M |
| Investing Cash Flow | -42.00K | -100.00K | -369.00K | -779.00K | -1.11M | -901.00K |
| Financing Cash Flow | 12.27M | 8.71M | 4.81M | 6.69M | -612.00K | 22.57M |
Micro-X Ltd. Technical Analysis
Micro-X Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$2.41B | -12.58 | -44.49% | ― | 55.91% | 22.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.31M | -2.88 | -103.74% | ― | 14.84% | 39.64% | |
44 Neutral | AU$98.30M | -5.21 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$163.11M | -14.95 | -70.55% | ― | ― | -257.32% | |
43 Neutral | AU$41.03M | 23.11 | -2.50% | ― | 25.72% | 84.69% | |
41 Neutral | AU$51.55M | -4.01 | -128.19% | ― | -14.25% | -22.83% |
Micro-X Ltd. Corporate Events
Micro-X Limited has released a presentation covering its financial results and operational update for the half year ended 31 December 2025. The document, approved by the board, is positioned as a high-level summary of the company’s assets, liabilities and performance, and refers investors to formal regulatory filings for comprehensive detail.
The company emphasises that the presentation is not an offer of securities or investment advice and highlights legal restrictions on distribution and sale, particularly in the United States. It also underscores that any forward-looking information is subject to uncertainty and risk, placing responsibility on investors to conduct their own analysis and seek professional advice before making investment decisions.
The most recent analyst rating on (AU:MX1) stock is a Sell with a A$0.07 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Limited reported a 155% surge in revenue to $10.1 million for the half-year to 31 December 2025, driven by growing sales of its X-ray technologies, while its net loss narrowed to $6.6 million, a 24% improvement on the prior corresponding period. The company’s adjusted loss, restated to exclude prior-year R&D cash rebates for comparability, fell by about 45%, but net tangible assets per share declined to 0.79 cents and auditors highlighted a material uncertainty over going concern, underlining that the business remains dependent on further revenue growth or funding to support its operations.
The most recent analyst rating on (AU:MX1) stock is a Sell with a A$0.07 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X has acknowledged that it has been listed on an Australian Government website as a project partner for an approved $1.5 million technology development grant. The company clarified that while negotiations with the named partners are at an advanced stage, a final development contract has not yet been fully executed, meaning the funding and associated project arrangements are not yet contractually secured.
The disclosure signals potential non-dilutive funding support that could further Micro-X’s technology development pipeline, but also underlines that the grant-related project is still subject to formal contractual completion. Stakeholders are effectively being cautioned that although the government has publicly named Micro-X as a recipient partner, the company cannot yet recognise the grant as definitive until all agreements are formally signed.
The most recent analyst rating on (AU:MX1) stock is a Sell with a A$0.07 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X has activated its first human pilot site for its Head CT stroke scanner at the Royal Melbourne Hospital, a leading comprehensive stroke centre and home to the Melbourne Brain Centre, marking the start of installation and commissioning ahead of world-first human imaging trials using its carbon nanotube CT technology. The in-hospital study, supported by the Australian Stroke Alliance and preceded by phantom testing and expert clinical evaluation, is intended to generate data for future regulatory applications, while additional test benches are being prepared for two further trial sites and parallel work continues on an in-ambulance Head CT prototype funded by the Australian Government’s Industry Growth Program, underscoring Micro-X’s push to transform pre-hospital stroke diagnosis by bringing high-quality brain imaging directly to patients.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has issued 2,255,927 fully paid ordinary shares under its incentive plan, expanding its share capital as part of its employee and executive remuneration structure. The company has confirmed that the shares were issued without a prospectus in reliance on existing disclosure provisions, and that it remains compliant with financial reporting and continuous disclosure obligations, with no additional material information required by investors to assess the company or the rights attached to the new shares, supporting transparency for existing and prospective shareholders.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has applied to the ASX for quotation of 1,453,664 new fully paid ordinary shares under its existing issuer code MX1. The additional shares, issued on 14 January 2026 following the exercise or conversion of existing securities, will modestly increase the company’s free float and tradable capital base, providing incremental liquidity for investors without materially altering its capital structure.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Limited has applied to the ASX for quotation of 802,263 new fully paid ordinary shares issued under its employee incentive scheme. The move modestly increases the company’s quoted capital base and reflects ongoing use of equity-based compensation to attract and retain staff, aligning employee interests with shareholders without signalling a major capital raising or change in strategic direction.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Limited has issued 26,874,854 unquoted performance rights under its employee incentive scheme, as disclosed in an Appendix 3G filing dated 13 January 2026. The grant of a substantial volume of performance rights indicates an ongoing use of equity-based compensation to incentivise and retain staff, which may support talent attraction and alignment of management interests with shareholders while modestly increasing potential future dilution for existing investors.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd., listed on the ASX under code MX1, has notified the market of changes to its issued capital structure. The announcement does not provide additional information on the company’s industry, products, or market focus.
The company has cancelled 580,293 performance rights (security code MX1AG) effective 13 January 2026, following an agreement between Micro-X and the holder. The cessation of these securities represents a minor capital structure adjustment and may marginally reduce future equity dilution for existing shareholders, but no broader operational or strategic implications were disclosed in the notice.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Limited has reported a change in the interests of director Ilona Meyer, as required under ASX listing rules. The company disclosed that Meyer’s holding of 127,877 unlisted performance rights has lapsed due to expiry, leaving her with 589,043 fully paid ordinary shares and 52,631 unlisted options, and confirmed that no trades occurred during a closed period and no consideration was involved in the change. The update clarifies the director’s current equity exposure and removes the previously held performance rights from the company’s overhang of potential equity, offering shareholders greater transparency over board-level incentives and potential future dilution.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Limited has announced the cessation of 4,103,330 performance rights (ASX code MX1AG) following their expiry without exercise or conversion on 13 January 2026. The lapse of these unexercised performance rights slightly simplifies the company’s capital structure and may modestly reduce potential future dilution for existing shareholders, but does not involve any cash movement or indicate an immediate change to operational activities.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has issued 18.75 million fully paid ordinary shares at $0.08 per share, expanding its share capital without providing a disclosure document under the fundraising provisions of the Corporations Act. The company has advised that it remains compliant with its financial reporting and continuous disclosure requirements and that there is no excluded or undisclosed information considered material for investors in assessing the company’s financial position, prospects, or the rights attached to the new shares, signalling that the capital raising is being conducted within standard regulatory settings and without additional risk disclosures for stakeholders.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has applied for quotation on the ASX of 18.75 million new fully paid ordinary shares, expanding the number of its listed securities. The new shares, issued on 30 December 2025 under a previously announced transaction, represent a capital raising or structural adjustment that will increase the company’s free float and potentially enhance liquidity for existing and new shareholders.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has applied to the ASX for quotation of 37.25 million new fully paid ordinary shares under its existing issuer code MX1. The securities, issued on 24 December 2025 as part of a previously announced transaction, will expand the company’s quoted share base, signalling a capital-raising or structural move that may affect ownership dispersion and liquidity for existing and new shareholders.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has issued 37,250,000 fully paid ordinary shares at $0.08 per share, increasing its capital base through a placement conducted without a prospectus under the exemption provisions of the Corporations Act. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations and stated there is no undisclosed market-sensitive information that investors would reasonably require, signalling that the capital raising is being carried out within the standard regulatory framework and without hidden risks for existing or new shareholders.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Limited announced its plan to issue up to 77,250,000 new ordinary fully paid shares, with the proposed issuance date set for December 24, 2025. This move is expected to provide additional capital, likely supporting the company’s growth initiatives and strengthening its position in the competitive medical imaging technology sector, enhancing its appeal to stakeholders and investors.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. has announced a $6 million capital raising initiative aimed at advancing the commercialization of its technologies and achieving various near-term strategic goals. As part of the development, the company’s strategic partner will increase their stake to 8.5%, signaling strengthened collaborative engagement and potential benefits for stakeholders through enhanced industry positioning.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X has raised $6.18M in its latest placement to fund critical commercial and manufacturing activities. With participation from key strategic investor Billion Prima, which increased its shareholding to 8.6%, and commitments from its chairman, this funding targets scaling up production of X-ray tubes and generators, advancing medical imaging initiatives like the Head CT product, and supporting partnerships in the security asset sector.
The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.